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Background: Unexpected differences in Ki-67 values among HER2 & ER/PgR defined subgroups were found. This
study aims to detect possible subdivisions beyond the conventional breast cancer types.
Methods: One thousand one hundred eighty consecutive patients with invasive ductal breast carcinoma were
included and distributed in 16 subgroups (four HER2 phenotypes (0+, 1+, 2+ and 3+) times four ER/PgR
phenotypes). Complex distributions of Ki-67 values were tested by expectation maximization (EM) clustering.
Results: Pooled Ki67 values of all patients showed the presence of three EM clusters (defined as LMA-low mitotic
activity, IMA-intermediate mitotic activity and HMA-high mitotic activity) with expected mean Ki-67 values of 1.17%,
40.45% and 77.79%, respectively. Only ER-PgR- tumors significantly dispersed in three clusters (29.75% tumors in
LMA, 46.95% in IMA and 23.30% in the HMA cluster), while almost no detected HMA tumors were of ER + PgR+ or
ER + PgR- phenotypes.
Among 799 ER + PgR+ patients distribution in clusters was HER2 dependent (p = 0.000243), due to increased
number of IMA HER2 3+ tumors on the expense of LMA HER2 3+ tumors (52 IMA out of 162 HER2 3+ patients
versus113 IMA out of 637 HER2 < 3+ patients). This was not found among ER + PgR- patients (p = 0.186968).
Among ER-PgR- patients, HER2 overexpression also increased number of IMA tumor, but by reducing the number
of HMA tumors (p < 0.000001). Here, difference between HER2 absent (0+) and HER2 3+ patients was evident
(10 HMA out of 125 HER2 3+ patients versus 42 HMA out of 103 HER2 0+ patients).
Conclusions: Results suggest that distributions of breast cancers in three clusters of mitotic activity depend on
different mechanisms for ER + PgR+ and ER negative tumors. Although HER2 overexpression increases number of
IMA tumors in both settings, in the former it is done by reducing number of LMA tumors, while in the latter it
reduces the number of HMA tumors. Mitotic activity of ER + PgR- tumors seems unrelated to the HER2 status,
possibly as an indicator that ER dysfunctionality in cancers that lack PgR expression. Among ER negative tumors,
the absence of HER2 (0+) might be as important as the HER2 overexpression.
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Despite many advances in cancer therapy, a majority of
all drugs are of variable effectiveness in patients with a
certain cancer type. In rare occasions (i.e. HER2 overex-
pressed breast cancer), a limited subgroup of patients
has been recognized as requiring a special type of
treatment, developed for their cancer variant. In many
other situations, the standard therapy is applied
according to the contemporary clinical guidelines.
From a clinical perspective, evidence-based decisions
on what type of therapy are to be used for a certain
patient remain a challenging task despite development
of new drugs.
In most cancer patients, contemporary stratification is
based on tumor tissue morphology and is not directly
related to the tumor biology, or treatment outcomes.
This means th at any well established cancer type or
subtype can contain several subgroups of patients whose
outcome might have been improved if they were recog-
nized as a specific subgroup and thus differently treated.
A new systematic approach to the patient stratification
according to tumor biology features found at the time of
diagnosis is needed to improve our results in treating
common cancer types. One of several possibilities is to
distribute new cancer patients in subgroups based on
tumor phenotype features previously validated as predic-
tors of tumor biology and/or treatment outcomes. Clinical
and histologic phenotype features linked to tumor biology
might lead to new targeted therapies for certain pa-
tient subgroups, in hope of achieving better treatment
outcomes.
In the diagnostic evaluation of breast cancer, estrogen
receptor (ER), progesterone receptor (PgR), human
epidermal growth factor receptor 2 (HER2) and Ki-67
are routinely used for the classification of breast tumors
into distinct subtypes [1, 2].
The prevailing contemporary classification of breast
tumors recognizes five basic immunohistochemical
phenotypes: Luminal A, Luminal B1 and Luminal B2 are
the three breast cancer types with positive ER or PgR
expression. Among breast cancers that are both ER and
PgR negative, two separate types are recognized, the
triple-negative and pure HER2 tumors. The former
tumors have normal HER2 expression (from 0+ to 2+),
while the latter show HER2 overexpression (3+).
It was proposed by the multistep model for breast
carcinogenesis suggests that invasive carcinoma arises
via a series of intermediate hyperplastic lesions through
various grades of atypia to in situ and invasive carcin-
omas [3]. This model thus assumes that there must be a
continuous phenotypic range of breast lesions that leads
to invasive ductal cancers instead of separate mecha-
nisms of occurrence for the five distinct breast cancer
types.Based on the report from the Clinical Cancer Registry
Regensburg in Bavaria, Germany, among 4480 patients
with non metastatic breast cancers, these immunohisto-
chemical results divided tumors in Luminal A (found in
48.4% patients), Luminal B (24.8% patients), HER2-like
(17.8% patients) and Basal-like (found in 9.0% patients)
[2]. In another report, among 267 patients with invasive
breast carcinomas, 44.9% of tumors were Luminal B
type, 21.7% Luminal A tumors, 18.7% triple-negative and
14.6% of pure HER2 type [4].
Breast cancer types are important in making thera-
peutic decisions. The presence of ER and PgR on tumor
cells at the time of surgery guides adjuvant therapy [5],
as an important predictor of both prognosis and hor-
mone dependency. It was reported that rare negative
ER/PgR positive breast cancers are biologically different
from ER positive/PgR positive tumors and have a poor
clinical outcome [6]. For instance, significant differences
in histologic grade (p < 0.001) and PgR expression
(p < 0.001) were reported between the Luminal A and B
types, leading to the conclusion that different manage-
ment guidelines should be considered for these two
breast cancer types [4]. It was also reported that accurate
classification of breast cancer patients as Luminal A, or
as Luminal B is important for determining effective
adjuvant treatment of ER positive and HER2 not over-
expressed tumors [7].
Results from a detailed analysis of histopathological
data of 1180 patients with invasive ductal breast cancer
are here presented. All patients have been treated in a
single regional medical center. Immunohistochemical
features of primary breast tumors were analyzed accord-
ing to their Ki-67 value, as a marker of mitotic activity.
This study was inspired by the distribution of Ki67
values regarding the HER2 expression status and ER/
PgR phenotype (shown in Fig. 1). Differences in ranges
and trends of Ki-67 values among the three common
ER/PgR phenotypes seem self-evident, so this paper is
aimed at detecting whether differences in tumor Ki-67
values among subgroups of patients are caused by the
existence of further subdivisions of tumors beyond usual
breast cancer types.
Methods
Patients
In this study 1180 consecutive invasive ductal breast
cancer patients (any stage) were included. All patients
were diagnosed and treated in Osijek Clinical Hospital
from the period January 2004 to December 2012. We
have used a single institution set of breast cancer
patients that has already been assembled as a part of a
research project financed by the Croatian Ministry of
Science (219–2,192,382-2426). Before grant submission to
Croatian Ministry of Science and Education, collecting of
Fig. 1 Histograms of Ki-67 values in groups of breast cancer patients accordingly to their immunohistochemical cancer phenotype
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mittee of Osijek Medical Faculty, as compliant with
the Helsinki Declaration. These same patients’ data
were used for testing two other breast cancer models
[8, 9] and the results of these testings were published
elsewhere [10, 11].
All of the specimens were excisional biopsies or
mastectomy specimens. Tumor grades were determined
using the Bloom and Richardson scheme [12–14].
Immunohistochemistry
All IHC slides were coded and independently evaluated
by two pathologists, who are also the coauthors of this
paper. They have used the ImageJ program tools
(https://imagej.nih.gov/ij/) when needed. Each immuno-
stained slide was evaluated for the presence of ER and
PgR expression, HER2 protein overexpression, and Ki–67
proliferation activity. Immunohistochemical staining was
done by the standard avidin-biotin method (DAKO
LSAB®2 System, HRP) using 4 μm sections from represen-
tative paraffin blocks. Nuclear staining with anti-ER, PgRand Ki-67 antibodies was also done and the percentage of
positive cells per 500 tumor cells was calculated.
Tumor cells were considered positive for HER2 pro-
tein over-expression when greater than 10% of the
cells showed strong membrane staining (equivalent to
a score of 3+ in the DakoCytomation HercepTest).
An HER2 2+ result was considered overexpressed
only if confirmed by chromogene in situ hybridization
for gene amplification. Hormone receptors were
reviewed and accepted as negative if 100% of cells
lacked nuclear immunostaining.
From our previous pilot study, we have noticed for the
Ki-67 values that the two independently estimated values
were usually less than 7% apart, so in all cases when
the difference was <6% we have used the arithmetic
mean of these two estimates as the final value. In less
than one fifth of patients, with the ki-67 gap >5%,
two new independent estimations were done. The
lowest and the highest value were discarded and the
arithmetic mean of the remaining two values was
used.
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In our first paper [10] we have used the 14% threshold in
separating Luminal A and Luminal B1 breast cancers. In
preparing the second paper [11], one of the main objection
of reviewers was that the threshold should be 20%, based
on the St. Gallen 2013 conclusion: ".. The Panel noted that
standardized cut-offs for Ki-67 have not been established
and laboratory specific values should be used, but the ma-
jority of the Panel voted that a threshold of >20% was
clearly indicative of ‘high' Ki-67 status" [15]. Beside that,
the same conclusions state: “.. The majority of the Panel
accepted that a useful surrogate definition of Luminal A-
like as distinct from Luminal B-like disease could be made
using a combination of ER, PgR and Ki-67, without requir-
ing molecular diagnostics” [15].
Based on the cited reference and to IHC results,
tumors of our patients were divided into following five
groups: Luminal A (ER+ and/or PgR+, HER2-negative,
Ki-67 < =20%), Luminal B1 (ER+ and/or PgR+, HER2-
negative, Ki-67 > 20%), Luminal B2 (ER+ and/or PgR+,
HER2-overexpressed, any Ki-67), HER2 (ER–, PgR–,
HER2-overexpressed), and triple-negative (ER–, PgR–,
HER2-negative).Table 1 Distribution of breast cancer patients according to the imm
ER/PgR expression HER2 phenotypes
Binary classification semiquantitative expression
ER + PgR+ “negative” 0+
1+
2+
“overexpressed” 3+
Total of patients with ER & PgR positive tumors
ER + PgR- “negative” 0+
1+
2+
“overexpressed” 3+
Total of patients with ER positive & PgR negative tumors
ER-PgR+ “negative” 0+
1+
2+
“overexpressed” 3+
Total of patients with ER negative & PgR positive tumors
ER-PgR- “negative” 0+
1+
2+
“overexpressed” 3+
Total of patients with ER & PgR negative tumors
Total of all patientsStatistical analysis
Collected data were organized in a spreadsheet by
StatSoft, Inc. (2011) STATISTICA (data analysis soft-
ware system), version 10. www.statsoft.com.
As shown in Table 1 the usual distribution of breast
cancers was based on HER2 expression, low or high Ki67
values and combinations of ER and PgR presence, thus
resulting in 16 subgroups (four HER2 variants (0+, 1+, 2+
and 3+) times four ER/PgR phenotypes).
Out of 16 subgroups in Table 1 ER-PgR+ subgroups
had too few patients to be used in statistical tests (only
11 patients), so they were excluded from further statistic
tests. Further more, out of the remaining 12 subgroups
(four with ER + PgR+, four with ER + PgR- and four
with ER-PgR- tumors), histograms of Ki-67 distributions
were made in Fig. 1 only for HER2 subgroups 0+, 1+
and 3+. The three omitted HER2 2+ cancer subgroups
were not suitable for histogram comparison, due to low
number of patients.
Complex distributions shown in Fig. 1 suggested that
more than one cluster of patients might be present in
each subgroup. Possible existence of clusters within a
single phenotypic subgroup was tested by applying theunohistochemical cancer phenotype
Breast cancer type Number of patients Total
Ki-67 < =20% Ki-67 > 20%
Luminal A/B1 248 90 338
165 68 233
44 19 63
Luminal B2 82 83 165
539 260 799
Luminal A/B1 15 10 25
14 12 26
4 3 7
Luminal B2 13 20 33
46 45 91
Luminal A/B1 1 3 4
3 2 5
2 0 2
Luminal B2 0 0 0
6 5 11
triple-negative 20 86 106
9 31 40
2 6 8
pure HER2 27 98 125
58 221 279
649 531 1180
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[16] to the original Ki-67 data of ER + PgR+, ER + PgR-
and ER-PgR- breast cancers (in total 12 subgroups). The
v-fold cross-validation algorithm for automatically deter-
mining the number of clusters in the data (provided by
the Statistica program) was applied during the clustering.
The EM algorithm of clustering approximates the ob-
served distributions of values by a mixture of distributions
in different clusters.
We have done a two-stage EM clustering. The first
stage is done within the described subgroups and it
suggested that all subgroup clusters belong to only three
clusters present in the whole set of patients. In the
second stage, all data were pooled together to verify
presence of these three overall clusters that were used in
further analysis.
Results
In this study 1180 consecutive patients with invasive
ductal breast cancers (regardless of stages) were in-
cluded. All patients were diagnosed and treated in Osijek
Clinical Hospital from January 2004 to December 2012.
Distribution of KI-67 values regarding ER/PgR and status
of HER2 expression
Distribution of Ki-67 values among the 16 proposed
phenotypic subgroups are shown in Table 1. Among
them, 11 out of 1180 patients (0.93%) showed the rarest
ER-PgR+ cancer phenotype, so in following tables these
11 patients were excluded, thus leaving 12 subgroups
with 1169 patients.
Figure 1 shows discrepancies between distributions of
Ki67 values among the remaining nine subgroups of
patients regarding their ER/PgR phenotype and HER2
expression (0+, 1+ or 3+, HER2 2+ tumors were omitted
due to low incidences). These data were validated by
Kruskal-Wallis tests:
 Among the ER + PgR+ tumors, Ki-67 values were
higher in HER2 3+ cancer than in tumors with low
HER2 expression (1+), or without any expression
(HER2 absent) (p < 0.0001).
 Among the ER + PgR- tumors, no difference in
Ki67 values, depending on the HER2 was found
(p = 0.3175).
 Particularly interesting were ER-PgR- tumors (in the
bottom row of Fig. 1). The highest levels of Ki-67
values are found in tumors without expression of
HER2 (HER2 absent). The presence of HER2 re-
duced KI-67 values slightly and this downslope holds
for the whole sequence of HER2 absent to HER2 3+.
The difference between the cancers without HER2
(HER2 absent) and cancers overexpressing HER2
(HER2 3+), was statistically significant (p = 0.0003).In short, if we compare cancers positive for ER and
PgR, where HER2 expression increases Ki67 values, with
the ER-PgR- cancers, were HER2 expression decreases
otherwise very high KI-67 values, these unexpected
differences obviously required further examinations. A
plausible interpretation is that even in these narrow
subgroups of breast cancers, unexpected distributions of
Ki67 values might result from further subgroup divisions.
The first stage EM clustering within subgroups of ER/PgR
and HER2 phenotypes
Table 2 shows results of the first stage EM clustering for
the analyzed subgroups. Figure 2 shows distributions of
EM clusters within nine subgroups analogous to the
histogram setting in Fig. 1. Despite our expectations, the
v-fold cross-validation algorithm detected only two
clusters of patients in each subgroup:
 In ER positive tumors, dominant clusters consisted
of patients with low Ki-67 values (columns labeled
LMA for Low Mitotic Activity, with mean values
from 10 to 16% in Table 2.). In two ER+ and HER2
3+ subgroups, the LMA analogous clusters showed
mean Ki67 values from 19 to 26%, suggesting that
HER2 overexpression increases Ki67 values of
tumors with low mitotic activity.
 In all HER2 absent (0+), HER2 1+ and HER2 2+
subgroups, one cluster contains patients whose
tumors show intermediate Ki-67 values (near 40%
are mean KI-67 values,), here defined as the IMA
clusters (from Intermediate Mitotic Activity)
 In ER positive tumors, the share of IMA clusters
declines with HER2 expression (among PgR+
cancers: from 25% of HER2 absent to 15% in HER2
3+; among PgR- cancers: from 40% in HER2 absent
to 6.1% in HER2 3+ cancers).
 In two ER+ HER2 3+ subgroups, the intermediate
range clusters shows mean Ki67 values 55 to 60%,
suggesting that among these tumors HER2
overexpression increased Ki67 values and reduced
share of IMA tumors.
 Among ER negative tumors HER2 expression did
not boost mitotic rates of dominant IMA clusters
(30 to 35%), but it reduced the share of the cluster
with high Ki67 values (high mitotic activity - HMA),
from 40% in HER2 absent tumors to 11.2 in HER2
3+ cancers, resulting in overall lower Ki-67 values
among the pure HER2 tumors.
The second stage EM clustering of the pooled data set
The above results of EM clustering in various subgroups
suggest that in all three analyzed ER/PgR phenotypes,
some patients had breast tumors that do not overexpress
HER2 and have similar intermediate mitotic activity
Table 2 Detected EM clusters of Ki-67 values within subgroups of breast cancer patients defined by certain immunohistochemical
phenotypes (LMA - low mitotic activity; IMA - intermediate mitotic activity; HMA - high mitotic activity). These are the results of the
first stage of EM clustering
ER/PgR phenotypes Breast cancer HER2 status
0+ 1+ 2+ 3+
ER + PgR+ Cancer types Luminal A/B1 Luminal B2
EM clusters LMA IMA LMA IMA LMA IMA LMA IMA
Patients n 255 83 187 46 52 11 139 26
% 75.4 24.6 80.3 19.7 82.5 17.5 84.2 15.0
Mean Ki-67% 9.5 39.1 11.3 39.6 13.5 38.6 19.2 56.6
St.dev. of Ki-67 6.1 15.2 7.2 11.1 6.9 9.5 10.1 10.3
ER + PgR- Cancer types Luminal A/B1 Luminal B2
EM clusters LMA IMA LMA IMA n/a LMA IMA
Patients n 15 10 20 6 7 31 2
% 60.0 40.0 76.9 23.1 n/a 93.9 6.1
Mean Ki-67% 9.7 42.4 15.5 39.0 25.4 60.0
St.dev. of Ki-67 5.4 14.8 8.6 6.0 13.3 7.1
ER-PgR- Cancer types triple-negative pure HER2
EM clusters IMA HMA IMA HMA n/a IMA HMA
Patients n 63 43 29 11 8 111 14
% 59.4 40.6 72.5 27.5 n/a 88.8 11.2
Mean Ki-67% 34.0 79.0 32.3 82.7 32.4 73.2
St.dev. of Ki-67 18.3 6.4 18.1 8.5 14.7 8.7
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clusters). On the other hand, clusters of low mitotic
activity (LMA) were present only in ER positive cancers
(both in PgR+ and PgR- cancers). Their share was
slightly reduced in subgroups with HER2 expression (1+
to 3+), suggesting that these tumors of low mitotic activ-
ity were hormone driven and thus less EGFR/HER2
dependent. Among ER-PgR- tumors, cancers of high mi-
totic activity formed the HMA clusters, more common
in variants poor in HER2 expression (HER2 0+ and 1+).
To test these observations, data of all patients were
pooled together and Ki67 values were tested for the
presence of three EM clusters (here defined as pooled
LMA, IMA and HMA clusters), shown in Table 3 and
Fig. 3 with mean Ki-67 values (LMA 1.17%, IMA 40.45%
and HMA 77.79%).
Table 4 shows unexpected distribution of our patients
according to their tumor type (Luminal A/B1, Luminal
B2, triple-negative and pure HER2) and cluster participa-
tion. A very few patients with ER+ tumors have been
classified as belonging to the overall HMA cluster (some
of them were PgR+ and other PgR-). On the other hand,
ER- patients were classified to belong to all three overall
clusters (29.75% LMA tumors, 46.95% IMA and 23.30%
HMA tumors), clearly suggesting that their distributionof Ki-67 values differs substantially from ER+ patients.
Dark grey cells in Table 4. mark the fields in which ob-
served frequencies were above the expected frequencies,
while the light grey cells mark the opposite situation in
which observed frequencies were below expectation.
 Among 799 ER + PgR+ patients distribution in
clusters was HER2 dependent (p = 0.000243), due to
increased number of IMA HER2 3+ tumors on the
expense of LMA HER2 3+ tumors (52 IMA out of
162 HER2 3+ patients versus113 IMA out of 637
HER2 < 3+ patients).
 This was not found among ER + PgR- patients
(p = 0.186968). Mitotic activity of ER + PgR- tumors
seems unrelated to HER2 status, possibly due to the
presence of “dysfunctional” ER that do not stimulate
PgR expression.
 Among ER-PgR- patients, HER2 overexpression also
increased number of IMA tumor, but by reducing
the number of HMA tumors (p < 0.000001). Here,
difference between HER2 absent (0+) and HER2 3+
patients was evident (10 HMA out of 125 HER2 3+
patients versus 42 HMA out of 103 HER2 0+ patients),
while patients with HER2 1+ or 2+ tumors did not
differ from the expected frequencies, suggesting that at
Fig. 2 Cluster distribution within nine subgroups of breast cancer patients (shown as histograms in Fig. 1) accordingly to their ER/PgR status and HER2
expression. The first stage of EM clustering detected two clusters of patients in each subgroups (marked here as clusters 1&2). In all subgroups one
cluster was of intermediate Ki-67 value (labeled IMA in Table 2), while the other showed either low (LMA in Table 2) or high values (HMA in Table 2)
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might be as important as the HER2 overexpression.
Taken all together, these results suggest that breast
cancers can be divided in three levels of mitotic activity,
with different mechanisms behind ER positive and ER
negative tumors. In the former HER2 overexpressionTable 3 Data of three EM clusters found in pooled data of 1169 bre
Breast cancer
patients
Three EM clusters from the pooled patients’ data
LMA (low mitotic activity) IMA (intermediate m
Mean Ki-67% 13.17 40.45
St.dev. of Ki-67 8.43 13.77
Breast cancer types n % n
Luminal A/B1 560 80.92 124
Luminal B2 126 63.64 68
triple-negative 41 26.62 58
pure HER2 42 33.60 73
Total 769 65.78 323
These are the results of the second stage of EM clustering that identified the three
mitotic activity; HMA - high mitotic activity). These are the results of the second staincreases number of IMA tumors on the expense of
LMA tumors, while in the latter HER2 overexpression
reduces number of HMA tumors. A possible interpret-
ation is that ER + PgR+ and ER negative breast tumors
are intrinsically so different that the HER2 overexpres-
sion reduces number of LMA ER + PgR+ tumors and
HMA ER-PgR- tumors. This is supported by theast cancer patients
Values for
all patientsitotic activity) HMA (high mitotic activity)
77.79 25.45
8.45 21.08
% n % Total %
17.92 8 1.16 692 100.00
34.34 4 2.02 198 100.00
37.66 55 35.71 154 100.00
58.40 10 8.00 125 100.00
27.63 77 6.59 1169 100.00
overall clusters of Ki-67 values (LMA - low mitotic activity; IMA - intermediate
ge of EM clustering
Fig. 3 Histogram of three EM clusters in the pooled data of 1169 breast cancer patients (LMA - low mitotic activity; IMA - intermediate mitotic
activity; HMA - high mitotic activity). These are the results of the second stage of EM clustering (details in Table 3)
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shares of LMA ER + PgR+ and of HMA ER-PgR-
cancers.
To make these observations more clear, distributions
of the pooled HER2 expression data within the three
clusters and three ER/PgR phenotypes are shown in
Fig. 4. as seven pie charts.
Discussion
Possible promitotic mechanisms in breast tumor IHC
phenotypes
Speed of the primary tumor growth mainly depends on
the mitotic rate (routinely estimated by the Ki67 value)
and on the rate of cancer cell destruction by apoptosis
and other mechanisms that threaten the survival of
tumor cells.
According to guidelines, breast cancer patients are
after surgery treated according to their cancer type.
Within Luminal tumors, Ki67 values define two cancer
types, Luminal B1 and Luminal B2. This means that im-
munohistochemical phenotype of tumor tissue somehow
influences the course of disease and effects of various
treatments including targeted drugs. Here reported dis-
parities in Ki-67 values between tumors with normally
expressed HER2 (subset of patients with cancers ex-
pressing HER2 from 0+ to 2+) suggest that five common
types of breast cancer are not as homogeneous as it can
be expected.
Table 5 shows an attempt to interpret here presented re-
lations between the phenotype variants and breast cancer
biology among our patients. Here proposed explanation is
that subgroups of breast cancer phenotypes differ in theirKi-67 distributions due to separate mechanisms that also
include Ki-67 dependency on HER2 expression:
 Ki-67 values of tumors with functional ER (ER + PgR
+ phenotype) seem dependent both on estrogen
exposure and on the status of HER2 expression
 LMA & IMA clusters of PgR negative phenotypes
(ER + PgR- and ER-PgR-) seem similar in their
distributions of HER2 values, so HER2 is an unlikely
candidate to explain increased Ki-67 values in IMA
clusters of these two phenotypes, suggesting that
some unknown promitotic mechanism might be
involved.
 Tumors lacking both ER and PgR with high Ki-67
values (HMA clusters with values >65%) seem
independent both of estrogen exposure and HER2
expression, so other promitotic mechanisms should
be considered.
A study by Wang XZ et al. [17] can be used as an
illustration that less recognized tumor growth mecha-
nisms have been proposed in triple-negative breast
cancer patients. They have analyzed 264 patients with
breast cancer divided into four molecular types plus the
expression of p53 and EGFR. Triple-negative and HER2
overexpressed cancers were found to be larger and with
higher Ki-67 as compared with the Luminal types.
Beside that, triple-negative tumors showed less positive
lymph nodes and higher CK5/6 and EGFR expression
than the other three types, while p53 expression posi-
tively correlated with the EGFR expression only among
triple-negative tumors, suggesting that tumor growth
Table 4 Distribution of breast cancer patients of a certain ER/PgR phenotype according to HER2 expression, tested by χ2 tests.
These are the results of the second stage of EM clustering that identified the three overall clusters of Ki-67 values. Dark grey marks
the fields in which observed frequencies were above the expected frequencies, while the light grey marks the opposite situation.
HER2 overexpression in ER+PgR+ cancers increased the share of IMA tumors and reduced the share of LMA tumors (p=0.000243).
Similar trends in ER+PgR- cancers were not significant (p=0.186968). Among ER-PgR- cancers, HER2 overexpression has reduced the
share of HMA tumors, while increasing shares of other two clusters, particularly of IMA tumors (p<0.000001)
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breast cancers [17].
In triple-negative tumors promitotic mechanisms can
include various mediators that do not interact with ER
and PgR. Beside androgen receptor, EGFR ligands, acti-
vin/inhibin interactions also seem plausible [18–20].
Based on these observations, Table 5 also addresses
few open questions regarding Immunohistochemical
phenotypes of tumors of the three clusters based on
their mitotic activity:
 If 168 cases out of our 769 breast cancers in the
LMA cluster were HER2 3+, does this suggest that
in these tumors HER2 molecules might bedysfunctional and thus result in unexpectedly low
Ki-67 values despite the HER2 overexpression?
 If 99 out of our 323 breast cancers in the IMA
cluster were HER2 absent, does this suggest that
another promitotic mechanism should be searched
for in HER2 absent & IMA tumors, particularly in
those 55 cancers showing the ER + PgR+ phenotype?
 If 43 out of 106 our triple-negative & HER2 absent
cancers belonged to the HMA cluster, is there some
special feature that promotes the highest mitotic
rates in triple-negative breast cancers with no HER2
molecules? It almost seems that among triple-
negative tumors any status of HER2 presence is
associated with a reduction in Ki-67 values.
Fig. 4 Pie charts of HER2 expression in three EM clusters of pooled breast cancer patients accordingly to their ER/PgR phenotype (LMA - low
mitotic activity; IMA - intermediate mitotic activity; HMA - high mitotic activity). These are the results of the second stage of EM clustering
(details in Table 4)
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The prevailing interpretation of the breast cancer occur-
rence is that increased or prolonged estrogen exposure
leads to an increased risk for the development of breast
cancer [21]. Estrogen via ER molecules stimulates prolif-
eration of breast cancer cells and regulates the expres-
sion of other proteins in the tumor cells, including the
progesterone receptor [22]. The presence of ER or PgR
on breast cancer cells typically suggests slower-growing
tumors, amenable to hormonal manipulation [23].
Here presented results suggest that the PgR expression
on breast cancer cells is related to the Ki-67 value, here
used as marker of tumor biology. It is important to note
that the role of PgR expression in breast cancer cells re-
mains not fully elucidated, since PgR expression is influ-
enced by the estrogen milieu [7] and it has been
reported that the lack of PgR in ER+ tumors is associ-
ated with worse survival [6]. A research study involving
327 ER+ breast cancer patients as shown that the Lu-
minal B patients with PgR- tumors had a relativelyhigher pathological complete response rate than patients
with PgR+ tumors (29.5% versus 4.7% pCR, P < 0.001),
but in Luminal B patients with a residual tumor after
neoadjuvant chemotherapy, PgR absence was independ-
ently correlated with poor relapse-free survival
(P = 0.017) and overall survival (P = 0.013) [24]. These
authors have concluded that the lack of PgR expression
might be an important determinant of tumor biology in
Luminal types of breast cancers.
Among 4115 patients with ER or PgR positive and not
HER2 overexpressed breast cancers, reduced cancer-free
intervals were noted in patients whose tumors had lower
PgR expression and higher Ki-67 value [25]. This is
possibly related to the second report that among 398
patients early relapses in patients with Luminal B and
HER2-negative breast cancers were related to PgR nega-
tivity [26].
It remains unsettled whether the PgR expression thresh-
old should be as low as 1% or higher. Among 1522
patients with primary breast cancer ER+/PgR−/HER2-
Table 5 The proposed interpretation of possible mechanisms behind distribution of Ki-67 values among subgroups of different
immunohistochemical cancer phenotypes
HER2 & ER/PgR
Breast cancer phenotypes
Model proposed subdivision of breast cancers, based on mitotic activity
LMA
(low mitotic activity)
Ki67 < 25%
IMA
(intermediate mitotic activity)
Ki-67 25–65%
HMA
(high mitotic activity)
Ki-67 > 65%
HER2
0+ to 3+
ER + PgR+ ~67% of all patients
probably HER2 dependent mitotic
rates, thus intermediate mitotic
rates seem dependent
on the increased HER2 expression
~ 1% of all patients
high mitotic rate due to
unknown promiotic mechanism
ER + PgR- ~26% of all patients
mitotic rates do not seem
closely regulated by normal
HER2 expression (0+ to 2+), HER2
3+ increases number of IMA tumors
ER-PgR- ~6% of all patients
high mitotic rate due to
unknown promiotic mechanism,
HER2 3+ reduces number of
HMA tumors
Open questions 168 out of 769 LMA cancers
were HER2 3+
Can HER2 molecules in
HER2 3+ & LMA cancers
be dysfunctional?
99 out of 323 IMA cancers were
HER2 absent
Is there another promitotic
mechanism in HER2 absent
& IMA tumors, particularly in
55 ER + PgR+ cancers?
43 out of 106 triple-negative
& HER2 absent cancers were HMA
What promotes the highest mitotic
rates in HER2 absent ER-PgR- tumors?
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compared with ER+/PgR+/HER2- tumors using a PgR
threshold of 20% instead of 1% [27]. In another report of
327 surgically removed ER positive and HER2 not-
overexpressed breast cancers, only among postmeno-
pausal patients it was reported that high Ki-67 value and
low PgR expression (<20%) were significant independent
factors for worse distant relapse-free survival [7].
Conclusions
A plausible interpretation of our results is that the inher-
ent mitotic activity of ER + PgR+ cancers is low and
HER2 overexpression can act as a promitotic factor in
some of these tumors showing the intermediate level of
mitotic activity. It remains possible that the PgR expres-
sion also plays an important role here, without PgR, the
link between the HER2 status and Ki-67 values vanishes.
On the other hand, ER negative tumors seem to be
inherently of very high mitotic activity, best evident in
HER2 absent tumors, suggesting that any HER2 expres-
sion in ER negative cancers reduces mitotic activity to
some extent. This means that at least among ER negative
breast tumors, HER2 absence (0+) should be validated as
a potential prognostic IHC feature.
Published reports open a question whether the altered
biology of ER + PgR- breast cancers results from
dysfunctional ER molecules (unable to promote the PgR
expression) [28–32]. A less obvious alternative is that
these tumors have normal ER, but due to some ER unre-
lated defect, cannot express PgR. In this case, the lack of
PgR ligands’ actions on tumor cells without PgR mightbe the cause of altered Ki-67 values. The answer to this
dilemma requires better understanding of interactions
between nuclear and membrane receptors for estrogen
and progesterone.
Nevertheless, the potential impact of here presented
findings regarding PgR expression and Ki-67 values on
patients’ management warrants a large prospective study
of DFS and overall survival among breast cancer patients
with various ER/PgR cancer phenotypes.
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